Jeremy Kortmansky

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

John D. Gordan, Erin B. Kennedy, Ghassan K. Abou‐Alfa et al. · Journal of Clinical Oncology · 2020 · 601 citations

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna C. Bendell et al. · The Lancet Oncology · 2019 · 543 citations · Full text

Cobimetinib Versus Regorafenib, Oncology, Medicine +10

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

Ignacio Durán, Jeremy Kortmansky, Deepti Singh et al. · British Journal of Cancer · 2006 · 316 citations · Full text

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

Ramesh K. Ramanathan, Shannon McDonough, Philip A. Philip et al. · Journal of Clinical Oncology · 2019 · 314 citations · Full text

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer

Stacey Stein, Edward James, Yanhong Deng et al. · British Journal of Cancer · 2016 · 209 citations · Full text